1-(3-methoxyphenyl)-3-(4-nitrophenyl)urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-methoxyphenyl)-3-(4-nitrophenyl)urea
• 英文别名: N-(3-methoxy-phenyl)-N'-(4-nitro-phenyl)-urea；N-(3-Methoxy-phenyl)-N'-(4-nitro-phenyl)-harnstoff
• 化学式: C₁₄H₁₃N₃O₄
• 分子量: 287.275
• InChiKey: SEYMHGVSIYPZRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  96.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-methoxyphenyl)-3-(4-nitrophenyl)urea 在 盐酸 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 、 正丁醇 为溶剂， 反应 3.83h， 生成 1-(3-methoxyphenyl)-3-[4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl]urea
  参考文献：
  名称：

  Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo

  摘要：

  We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo [3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis using cell- and transgenic-zebrafish-based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once daily dose of compound 33 at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound 33.

  DOI：

  10.1021/jm301537p
• 作为产物：
  描述：

  4-硝基苯胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 1-(3-methoxyphenyl)-3-(4-nitrophenyl)urea
  参考文献：
  名称：

  Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo

  摘要：

  We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo [3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis using cell- and transgenic-zebrafish-based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once daily dose of compound 33 at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound 33.

  DOI：

  10.1021/jm301537p

文献信息

• Über den Umsatz aromatischer Isocyansäure-ester mit aromatischen Aminen
  作者：C. Naegeli、A. Tyabji、L. Conrad

  DOI：10.1002/hlca.193802101140

  日期：——

  1. Wenn aromatische Isocyansäure-ester mit aromatischen Aminen in aromatischen Kohlenwasserstoffen sich miteinander umsetzen, so ordnen sich die Substituenten bezüglich ihres Einflusses auf die Aktivität der Isocyansäure-Gruppe in die Reihe

  1.当芳族异氰酸酯与芳烃中的芳族胺反应时，取代基将根据其对异氰酸酯基活性的影响进行排序
• Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents
  作者：Amna Ghith、Khairia M. Youssef、Nasser S.M. Ismail、Khaled A.M. Abouzid

  DOI：10.1016/j.bioorg.2018.10.008

  日期：2019.3

  compound 10a. Flow cytometric analysis on both MCV-7 and PC-3 cancer cells revealed that it induced cell-cycle arrest in the G0-G1phase and reinforced apoptosis via activation of caspase-3. Furthermore, molecular modeling studies have been carried out to gain further understanding of the binding mode in the active site of VEGFR-2 enzyme and predict pharmacokinetic properties of all the synthesized inhibitors

  设计，合成和评价了不同系列的新型噻吩并[2，3- d ]嘧啶衍生物（9a-d，10a-f，l，m和15a-m）在体外抑制VEGFR-2酶的能力。而且，通过NCI对60种不同的人类癌细胞系进行了测试，以测试最终化合物的细胞毒性。VEGFR-2酶的抑制结果表明，化合物10d，15d和15 g是活性最高的抑制剂，IC 50值分别为2.5、5.48和2.27 µM，而化合物10a显着显示出最高的细胞生长抑制率，平均生长抑制率（GI）为31.57％。它对几种NCI细胞系表现出广谱的抗增殖活性，特别是对人乳腺癌（T7-47D）和肾癌（A498）细胞系分别具有85.5％和77.65％的抑制作用。为了研究该活性的机制，对化合物10a进行了进一步的生物学研究，例如流式细胞术细胞周期与caspase-3比色测定。对MCV-7和PC-3癌细胞的流式细胞仪分析表明，它诱导了G0-G1期的细胞周期停滞，并通过激活c
• 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation
  作者：Mahitab K. Sobhy、Samar Mowafy、Deena S. Lasheen、Nahla A. Farag、Khaled A.M. Abouzid

  DOI：10.1016/j.bioorg.2019.102988

  日期：2019.8

  modelling protocols prior to the synthesis and biological evaluation of the derivatives. First, sorafenib was docked in the binding site of VEGFR 2 to study its binding orientation and affinity, followed by the generation of a valid 3D QSAR pharmacophore model for use in the virtual screening of different 3D databases. Structures with promising pharmacophore-based virtual screening results were refined using

  成功设计，合成和评估了一系列新颖的6,7-二氢-5H-环戊[d]嘧啶衍生物，作为具有血管内皮生长因子受体（VEGFR 2）抑制活性的新型化学支架。化合物6c和6b在10 µM时分别显示97％和87％的酶抑制，并显示出有效的剂量相关VEGFR 2抑制，IC50值分别为0.85 µM和2.26 µM。6,7-二氢-5H-环戊[d]嘧啶骨架的设计是通过连续的分子建模方案进行的，然后进行衍生物的合成和生物学评估。首先，将索拉非尼停靠在VEGFR 2的结合位点以研究其结合方向和亲和力，然后生成有效的3D QSAR药效团模型，用于虚拟筛选不同的3D数据库。通过在VEGFR 2的结合位点进行分子对接研究，对具有前景的基于药效团的虚拟筛选结果的结构进行了改进。通过结合药效团模型生成和分子对接研究的结果，设计了一种新型支架。新的支架显示出与激酶前袋的疏水相互作用，这可能归因于在VEGFR 2中的停留时间增加
• Molecular design, synthesis and <i>in vitro</i> biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer
  作者：Mona M. Abdel-Atty、Nahla A. Farag、Rabah A. T. Serya、Khaled A. M. Abouzid、Samar Mowafy

  DOI：10.1080/14756366.2021.1933465

  日期：2021.1.1

  pharmacophore of EGFR, VEGFR2 into the inhibitory functionality of HDAC6. Three compounds (12c, 15b and 20b) were promising hits, whereas (12c) exhibited potent VEGFR2 inhibition (IC50=185 nM), potent EGFR inhibition (IC50=1.14 µM), and mild HDAC6 inhibition (23% inhibition). Moreover, compound (15c) was the most potent dual inhibitor among all the synthesised compounds, as it exhibited potent EGFR and VEGFR2

  抽象的 通过将EGFR、VEGFR2的药效团结合到HDAC6的抑制功能中，设计并合成了一系列基于噻吩并[2,3- d ]嘧啶的异羟肟酸杂合体作为多靶点抗癌药物。三种化合物（12c、15b 和 20b）是有希望的命中，而（12c）表现出有效的 VEGFR2 抑制（IC 50 = 185 nM）、有效的 EGFR 抑制（IC 50 = 1.14 µM）和轻度 HDAC6 抑制（抑制 23%）。此外，化合物(15c)是所有合成化合物中最有效的双重抑制剂，因为它分别表现出有效的EGFR和VEGFR2抑制作用(IC 50 =19 nM)和(IC 50 =5.58 µM)。而化合物(20d)和(7c)分别表现出纳摩尔选择性激酶抑制作用，EGFR I​​C 50 = 68 nM，VEGFR2 IC 50 = 191 nM。所有合成的化合物均在体外筛选其对 60 种人类 NCI 肿瘤细胞系的细胞毒作用。此外，还进行了分子对接研究和
• Über die Einwirkung von Wasser auf aromatische lsocyansäure-ester
  作者：C. Naegeli、A. Tyabji、L. Conrad、F. Litwan

  DOI：10.1002/hlca.193802101139

  日期：——

  1. Die Reaktionswege, die bei Umsatz aromatischer Isocyansäure-ester mit Wasser zum zugehörigen Diarylharnstoff bzw. zum entsprechenden Arylamin führen, wurden systematisch untersucht: (a) durch den Umsatz der Isocyanate mit Wasser unter verschiedenartigen Bedingungen; (b) durch den Umsatz mit Arylaminen in Benzol-Toluol-Lösung; (c) durch den gleichzeitigen Umsatz mit Wasser und Arylamin in Aceton;

  1.已经系统地研究了使芳族异氰酸酯与水反应时导致缔合的二芳基脲或相应的芳基胺的反应途径：（a）通过在不同条件下使异氰酸酯与水反应；（b）通过与芳胺在苯-甲苯溶液中的转化；（c）与水和芳基胺在丙酮中同时反应；（d）通过转换获得2％的收益。钾碱液和不同浓度的盐酸；（e）通过用甲醇转化。实验结果为z。部分内容在表1（p。1102）中，然后用文字简要概述。参考了实验的制备重要性（第1101、1118和1125页）。